Search

Your search keyword '"Nektar Therapeutics"' showing total 1,417 results
Start Over Descriptor "Nektar Therapeutics"
1,417 results on '"Nektar Therapeutics"'

10. Wall Street is Overlooking This Penny Stock, Says Analyst

Author

Gupta, Ruchi

Subjects
Nektar Therapeutics, Biotechnology industry, Stocks, Business
Abstract

Penny stocks are best reserved for investors with a healthy risk appetite, since these shares are often tied to companies that are unprofitable or even pre-revenue. However, for those who [...]

Published
2024

11. Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024

Subjects
Nektar Therapeutics, Biotechnology industry, General interest, News, opinion and commentary
Abstract

Global Banking News-September 25, 2024-Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024 (C)2024 ENPublishing - http://www.enpublishing.co.uk Clinical-stage biotechnology company Nektar Therapeutics (Nasdaq: NKTR) on Wednesday announced multiple presentations for rezpegaldesleukin (REZPEG) [...]

Published
2024

12. Iambic Therapeutics Adds Dr. Mary Tagliaferri to Its Board of Directors

Subjects
Nektar Therapeutics, Biotechnology industry, Boards of directors, Arts and entertainment industries
Abstract

Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its AI-driven discovery platform, reported that Mary Tagliaferri, M.D., has joined its Board of Directors. A biotech industry veteran, the [...]

Published
2024

14. Nektar Therapeutics Files SEC Form EFFECT, Notice of Effectiveness: (Jun. 6, 2024)

Subjects
United States. Securities and Exchange Commission, Nektar Therapeutics, Biotechnology industry, Physical fitness, Health
Abstract

2024 JUN 29 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2024

15. Nektar Therapeutics Files SEC Form 424B3, Prospectus [Rule 424(B)(3)]: (Jun. 5, 2024)

Subjects
United States. Securities and Exchange Commission, Nektar Therapeutics, Securities law, Biotechnology industry, Physical fitness, Health
Abstract

2024 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2024

17. Nektar: NKTR-0165 shows selective enhancement of treg cell function in study

Subjects
Nektar Therapeutics, Biotechnology industry, Tumor necrosis factor, Business, News, opinion and commentary
Abstract

Nektar Therapeutics announced the presentation of a poster highlighting new preclinical data on NKTR-0165 at the European Alliance of Associations for Rheumatology 2024 Congress. NKTR-0165 is a novel, first-in-class tumor [...]

Published
2024

20. Nektar Therapeutics Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material: (Apr. 26, 2024)

Subjects
United States. Securities and Exchange Commission, Nektar Therapeutics, Securities law, Biotechnology industry, Proxy, Physical fitness, Health
Abstract

2024 MAY 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2024

23. 8-K: Septerna, Inc

Subjects
Nektar Therapeutics
Abstract

(EDGAR Online via COMTEX) -- false 0001984086 0001984086 2024-12-06 2024-12-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of [...]

Published
2025

24. Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Subjects
Nektar Therapeutics
Abstract

ENPNewswire-December 9, 2024--Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting (C)2024 [...]

Published
2024

25. Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Subjects
Nektar Therapeutics, T cells, Diseases -- Relapse, Lymphomas -- Care and treatment, Business, News, opinion and commentary
Abstract

73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area [...]

Published
2024

26. 8-K: NEKTAR THERAPEUTICS

Subjects
Nektar Therapeutics, Business, general
Abstract

(EDGAR Online via COMTEX) -- false 0000906709 0000906709 2024-12-02 2024-12-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section [...]

Published
2024

27. Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Subjects
Nektar Therapeutics, Incyte Corp., Non-Hodgkin lymphomas, Clinical trials, Business research, Emapalumab, Nivolumab, Acalabrutinib, Pharmaceutical industry, Cemiplimab, Business -- Research, Non-Hodgkin's lymphomas
Abstract

LAS VEGAS: DelveInsight Business Research, LLP has issued the following news release: DelveInsight's 'Follicular Lymphoma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline follicular lymphoma therapies in various [...]

Published
2024

29. NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Subjects
United States. Food and Drug Administration, Nektar Therapeutics, Fate Therapeutics Inc., Innate Pharma, Business -- Research, Biotechnology industry, Killer cells, Clinical trials, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

LAS VEGAS: DelveInsight Business Research, LLP has issued the following news release: DelveInsight's 'NK Cell Therapy Pipeline Insight 2024' report provides comprehensive global coverage of pipeline NK cell therapies in [...]

Published
2024

30. 10-Q: NEKTAR THERAPEUTICS

Subjects
Nektar Therapeutics, Cybernet Data Systems Inc., Eli Lilly and Co., Computer services industry, Biotechnology industry, Pharmaceutical industry, Computer services industry, Business, general
Abstract

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion contains forward-looking statements that involve risks and uncertainties. Our [...]

Published
2024

31. Nektar Therapeutics Reports Third Quarter 2024 Financial Results

Subjects
Nektar Therapeutics, Biotechnology industry
Abstract

ENPNewswire-November 8, 2024--Nektar Therapeutics Reports Third Quarter 2024 Financial Results (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 07112024 - SAN FRANCISCO - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for [...]

Published
2024

32. Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients

Subjects
Nektar Therapeutics, Biotechnology industry
Abstract

ENPNewswire-November 8, 2024--Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients (C)2024 [...]

Published
2024

33. Nektar Therapeutics to Participate in Upcoming Investor Conferences

Subjects
Nektar Therapeutics, Biotechnology industry, General interest, News, opinion and commentary
Abstract

SAN FRANCISCO: Nektar Therapeutics has issued the following news release: Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global [...]

Published
2024

34. Nektar Therapeutics to Participate in Upcoming Investor Conferences

Subjects
Nektar Therapeutics, Biotechnology industry, Business, News, opinion and commentary
Abstract

SAN FRANCISCO, Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare Conference in [...]

Published
2024

45. Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Subjects
Nektar Therapeutics, T cells, Diseases -- Relapse, Lymphomas -- Care and treatment, Business, Health, Health care industry
Abstract

2024 DEC 24 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Nektar Therapeutics (Nasdaq: NKTR) announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as [...]

Published
2024

46. Treg Cell-based Therapies Clinical Trial Pipeline Appears Robust With 51+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Subjects
Business -- Research, Biotechnology industry, Immunotherapy, Clinical trials, Pharmaceutical industry, Nektar Therapeutics
Abstract

2024 NOV 13 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- DelveInsight's ' Treg Cell-based Therapies Pipeline Insight 2024' report provides comprehensive global coverage of available, [...]

Published
2024

49. Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

Subjects
Nektar Therapeutics, Atopic dermatitis, Biotechnology industry, General interest, News, opinion and commentary
Abstract

SAN FRANCISCO: Nektar Therapeutics has issued the following press release: Nektar Therapeutics (Nasdaq: NKTR) today announced several presentations for rezpegaldesleukin (REZPEG) at the 2024 European Academy of Dermatology and Venereology [...]

Published
2024

50. Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

Subjects
Nektar Therapeutics, Atopic dermatitis -- Analysis, Biotechnology industry -- Analysis, Proteins -- Analysis, Business, News, opinion and commentary
Abstract

- New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing specific serum proteins known to be elevated in patients with atopic dermatitis - SAN [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results